replicates in triplicate (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC replicates in triplicate
Replicates In Triplicate, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 175 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/triplicate+replication/IV%2E3/pmc03910836-185-9-27
Average 94 stars, based on 175 article reviews

replicates in triplicate - by Bioz Stars, 2026-09

94/100 stars

Images

other:

Article Title: Binding molecules specific for fcγRIIA and uses thereof
Article Snippet: The hybridoma cell line was obtained from ATCC and the heavy chain variable (VH) and light chain variable (VL) segments of IV.3 were sequenced (SEQ ID NO: 5 and SEQ ID NO: 8).

Control:

Article Title: Head and neck squamous cell carcinoma-derived extracellular vesicles mediate Ca²⁺-dependent platelet activation and aggregation through tissue factor.
Article Snippet: .. For the experiments involving the IV.3 antibody, heat-inactivated and immunoglobulin G (IgG)-coated Escherichia coli (ATCC® 25922TM; 5 × 107/aggregometer run) served as control. ..

Article Title: Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Ukraine: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
Article Snippet: .. To fully assess antibiotics where high-dose therapies are available, susceptibility using EUCAST criteria was also calculated by combining percentage susceptible and susceptible, increased exposure into the susceptible category.11 The antibiotics with high-dose availability assessed in this way included the following: amoxicillin (0.75–1 g oral, 3× daily), amoxicillin/clavulanic acid (0.875 g amoxicillin/0.125 g clavulanic acid oral, 3× daily), ampicillin [2 g intravenous (IV), 4×daily], penicillin (2.4 g IV, 2 MU 4–6× daily), ceftriaxone (2 g IV, 2× daily), clarithromycin (0.5 g oral, 2× daily), erythromycin (1 g oral or IV, 4× daily), levofloxacin (0.75 g oral 2× daily, or 0.4 g IV 3× daily) and trimethoprim/sulfamethoxazole (0.24 g trimethoprim/1.2 g sulfamethoxazole oral or IV, 2× daily).11 Quality control and data analysis Quality control strains S. pneumoniae ATCC 49619, H. influenzae ATCC 49247, H. influenzae ATCC 49766 and E. coli ATCC 32518 were included on each day of testing. ..

Article Title: Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Pakistan: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
Article Snippet: .. To fully assess antibiotics where high-dose therapies are available, susceptibility using EUCAST criteria was also calculated by combining percentage susceptible and susceptible, increased exposure into the susceptible category as well as dose-dependent PK/ PD breakpoints.15,16 The antibiotics with high-dose availability assessed in this way were as follows: amoxicillin (0.75–1 g oral, 3× daily), amoxicillin/clavulanic acid (0.875 g amoxicillin/0.125 g clavulanic acid oral, 3× daily), ampicillin (2 g intravenous [IV], 4× daily), penicillin (2.4 g IV, 2 MU 4–6× daily), ceftriaxone (2 g IV, 2× daily), clarithromycin (0.5 g oral, 2× daily), erythromycin (1 g oral or IV, 4× daily), levofloxacin (0.75 g oral 2× daily or 0.4 g IV 3× daily) and trimethoprim/sulfamethoxazole (0.24 g trimethoprim/1.2 g sulfamethoxazole oral or IV, 2× daily).15 Quality control and data analysis Quality control strains S. pneumoniae ATCC 49619, H. influenzae ATCC 49247, H. influenzae ATCC 49766 and E. coli ATCC 32518 were included on each day of testing. ..

Article Title: Results from the Survey of Antibiotic Resistance (SOAR) 2018-21 in Kuwait and the United Arab Emirates: data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
Article Snippet: .. To fully assess antibiotics where high-dose therapies are available, susceptibility using EUCAST criteria was also calculated by combining percentage susceptible and susceptible, increased exposure into the susceptible category.16 The antibiotics with high-dose availability assessed in this way were as follows: amoxicillin (0.75–1 g oral, 3× daily), amoxicillin/clavulanic acid (0.875 g amoxicillin/ 0.125 g clavulanic acid oral, 3× daily), ampicillin (2 g IV, 4× daily), penicillin (2.4 g IV, 2 MU 4–6× daily), ceftriaxone (2 g IV, 2× daily), clarithromycin (0.5 g oral, 2× daily), erythromycin (1 g oral or IV, 4× daily), levofloxacin (0.75 g oral 2× daily, or 0.4 g IV 3× daily) and trimethoprim/sulfamethoxazole (0.24 g trimethoprim/1.2 g sulfamethoxazole oral or IV, 2× daily).16 Quality control and data analysis Quality control strains S. pneumoniae ATCC 49619, H. influenzae ATCC 49247, H. influenzae ATCC 49766 and Escherichia coli ATCC 32518 were included on each day of testing. ..

Purification:

Article Title: A genetically determined molecular switch modulates the anti-inflammatory potential of human IgA
Article Snippet: .. Hybridomas secreting anti-FcγRIa mAb 32.2 and anti-FcγRIIa mAb IV.3 were from ATCC (Manassas, VA, USA), and the secreted antibodies were purified by Protein A affinity chromatography. .. The anti-His6G, anti-GST, and anti-CK1δ mAbs were from Thermo Fisher Scientific (Grand Island, NY, USA).

Article Title: A genetically determined molecular switch modulates the anti-inflammatory potential of human IgA.
Article Snippet: .. Hybridomas secreting anti-FcgRIa mAb 32.2 and anti-FcgRIIa mAb IV.3 were from ATCC (Manassas, VA, USA), and the secreted antibodies were purified by Protein A affinity chromatography. .. The anti-His6G, anti-GST, and anti-CK1d mAbs were from Thermo Fisher Scientific (Grand Island, NY, USA).

Review

replicates in triplicate (ATCC)

Structured Review

Images

Related Articles

other:

Control:

Purification:

Affinity Chromatography:

Similar Products

Image Search Results